Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
In This Article:
Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.
Oops, something went wrong
Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.